Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The Minister of Public Health Dr. Firass Abiad at COP28 in UAE

 
The Minister of Public Health (MoPH), Dr. Firass Abiad, will be participating in the COP28 held in UAE from November 30 to December 12, where leaders from around the world convene annually to address the dangerous human interference with the climate system. The Minister’s participation in COP28 UAE is particularly important as it would be the first COP with an explicit health focus. Dr. Abiad, the Minister of Public Health, Eng. Joyce Haddad, the Director of Preventive Healthcare at MoPH, Dr. Myriam Mrad, the Director of the Public Health Department at the University of Balamand and the Ministry Technical Collaborator will be representing the ministry of public health in the Lebanese national delegation.  

Minister Abiad will emphasize the imperative need to prioritize public health concerns in Lebanon within the broader discourse on climate change. Acknowledging the undeniable impact of environmental factors on human health, Dr. Abiad will commit to advocate for proactive measures and collaborative strategies to mitigate these effects in Lebanon.

The Minister will stress key initiatives aiming at safeguarding public health amidst environmental shifts, emphasizing the urgency of adaptation measures and the development of resilient healthcare systems. These initiatives align with the Lebanese Ministry of Public Health's commitment to promoting sustainable health practices and ensuring equitable access to healthcare for all citizens.

Additionally, Dr. Abiad will participate in high-level dialogues, fostering collaborations with global stakeholders and reaffirming Lebanon's dedication to the global fight against climate change, particularly in preserving public health.

It is worth noting that earlier this year, the MoPH endorsed COP26 proceedings in an official letter signed and dated March 26, 2023.  As part of this initiative, Lebanon committed to prioritizing the health needs of its population, while simultaneously addressing the environmental and sustainability challenges facing its healthcare facilities.

The MoPH remains steadfast in its commitment to integrating climate resilience into public health policies, aligning efforts with international agendas to safeguard the well-being of citizens and future generations.
    1
    ...
ATC Name B/G ↓ Ingredients Dosage Form Price
L01XG01 VELZOME G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 18,154,041 L.L
B01AF01 VAROXA G Rivaroxaban - 15mg 15mg Tablet, film coated 1,343,843 L.L
J05AH02 VIRIFLU G Oseltamivir - 75mg 75mg Capsule 1,371,615 L.L
B01AF01 VAROXA G Rivaroxaban - 20mg 20mg Tablet, film coated 1,343,843 L.L
J01CR02 VAAMOX IV G Amoxicillin - 1g, Clavulanic Acid - 200mg Injectable powder 225,766 L.L
J01CR02 VAAMOX IV G Amoxicillin - 1g, Clavulanic Acid - 200mg Injectable powder 2,150,148 L.L
J05AR06 VITRICOMB G Emtricitabine - 200mg, Tenofovir disoproxil fumarate - 300mg, Efavirenz - 600mg Tablet, film coated 22,191,783 L.L
B01AF01 VAROXA G Rivaroxaban - 10mg 10mg Tablet, film coated 2,879,854 L.L
A10BH02 VILDAVITAE G Vildagliptin - 50mg 50mg Tablet 665,202 L.L
A10BH02 VILDIAB G Vildagliptin - 50mg 50mg Tablet 806,306 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
A10BH02 VLUDIN G Vildagliptin - 50mg 50mg Tablet 767,910 L.L
N07CA01 VASOSERC FORTE G Betahistine dihydrochloride - 16mg 16mg Tablet 944,529 L.L
N07CA01 VERTINEX G Betahistine dihydrochloride - 16mg 16mg Tablet, scored 1,204,339 L.L
N07CA01 VERTINEX G Betahistine dihydrochloride - 16mg 16mg Tablet 371,157 L.L
N07CA01 VASOSERC G Betahistine dihydrochloride - 8mg 8mg Tablet 1,334,884 L.L
N07CA01 VASOSERC BID G Betahistine dihydrochloride - 24mg 24mg Tablet 840,861 L.L
N07CA01 VERTINEX G Betahistine dihydrochloride - 24mg 24mg Tablet, scored 921,492 L.L
G04BE03 VIGOR-50 G Sildenafil (citrate) - 50mg 50mg Tablet, film coated 332,761 L.L
G04BE03 VIGORAM G Sildenafil citrate - 50mg 50mg Tablet 330,585 L.L
G04BE03 VONTA G Sildenafil citrate - 50mg 50mg Tablet, film coated 335,961 L.L
G04BE03 VONTA G Sildenafil citrate - 50mg 50mg Tablet, film coated 90,037 L.L
C09CA03 VALSANET G Valsartan - 80mg 80mg Tablet, film coated 479,944 L.L
C09CA03 VALSARTAN ARROW LAB G Valsartan - 80mg 80mg Tablet, film coated, breakable 387,027 L.L
C09CA03 VIOSTAN 80 G Valsartan - 80mg 80mg Tablet, film coated 526,786 L.L
G04BE03 VIRECTA G Sildenafil - 100mg 100mg Tablet, film coated 584,571 L.L
C09CA03 VALSANET G Valsartan - 160mg 160mg Tablet, film coated 560,574 L.L
C09CA03 VALSARTAN ARROW LAB G Valsartan - 160mg 160mg Tablet, film coated, breakable 473,033 L.L
C09CA03 VALUSTAR G Valsartan - 160mg 160mg Tablet, film coated 634,294 L.L
C09CA03 VIOSTAN 160 G Valsartan - 160mg 160mg Tablet, film coated 668,082 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025